Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Sonneveld, Pieter; Α. Dimopoulos, Meletios; Boccadoro, Mario; Quach, Hang; Joy Ho, P.; Beksaç, Meral; Hulin, Cyrille; Antonioli, Elisabetta; Leleu, Xavier; Mangiacavalli, Silvia; Perrot, Aurore; Cavo, Michèle; Belotti, Angelo; Broijl, Annemiek; Gay, Francesca; Mina, Roberto; S. Nijhof, Inger; W.C.J. van de Donk, Niels; Katodritou, Eirini; Schjesvold, Fredrik; Sureda, Anna; Rosiñol, Laura; Delforge, Michel; Roeloffzen, Wilfried; Silzle, Tobias; Juul Vangsted, Annette; Einsele, Hermann; Spencer, Andrew; Hájek, Roman; Jurczyszyn, Artur; Lonergan, Sarah; Ahmadi, Tahamtan; Liu, Yanfang; Wang, Jianping; Vieyra, Diego; M.J. van Brummelen, Emilie; Vanquickelberghe, Véronique; Sitthi-Amorn, Anna; J. de Boer, Carla; Carson, Robin; Rodríguez‐Otero, Paula; Bladé, Joan; Moreau, Philippe

doi:10.1056/nejmoa2312054

Public

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Published in New England Journal of Medicine • Dec 12, 2023

Authors:

Pieter Sonneveld

Meletios Α. Dimopoulos

Mario Boccadoro

Abstract

BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnos...

Subject

Daratumumab

Lenalidomide

Bortezomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!